Skip to main content
Top
Published in: Cardiovascular Diabetology 1/2015

Open Access 01-12-2015 | Original investigation

Increased FGF23 serum level is associated with unstable carotid plaque in type 2 diabetic subjects with internal carotid stenosis

Authors: Federico Biscetti, Giuseppe Straface, Carlo Filippo Porreca, Giovanni Bertoletti, Claudio Vincenzoni, Francesco Snider, Egidio Stigliano, Vincenzo Arena, Flavia Angelini, Giovanni Pecorini, Antonio Bianchi, Raffaele Landolfi, Andrea Flex

Published in: Cardiovascular Diabetology | Issue 1/2015

Login to get access

Abstract

Background

The object of this study was to investigate the potential role of FGF23 on plaque stability in type 2 diabetic patients with internal carotid artery stenosis.

Methods

In this retrospective observational study, we analyzed FGF23 serum level in 361 type 2 diabetic patients with internal carotid artery stenosis undergoing carotid endarterectomy and in 598 diabetic controls without carotid atherosclerosis.

Results

We found that FGF23 median serum levels was significantly higher in patients than in diabetic controls [67.7 (59.5–77.8) pg/mL and 43.89 (37.5–50.4), P < 0.001] and was significantly and independently associated with unstable plaque in patients with internal carotid artery stenosis [OR, 5,71 (95 % CI, 2.09–15.29].

Conclusions

We have found, for the first time, that FGF23 could be associated with unstable plaque in type 2 diabetic patients with internal carotid artery stenosis.
Literature
2.
3.
7.
go back to reference Jean G, Terrat JC, Vanel T, Hurot JM, Lorriaux C, Mayor B, et al. High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients. Nephrol Dial Transpl. 2009;24:2792–6. doi:10.1093/ndt/gfp191.CrossRef Jean G, Terrat JC, Vanel T, Hurot JM, Lorriaux C, Mayor B, et al. High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients. Nephrol Dial Transpl. 2009;24:2792–6. doi:10.​1093/​ndt/​gfp191.CrossRef
8.
go back to reference Mirza MA, Hansen T, Johansson L, Ahlstro¨m H, Larsson A, Lind L, et al. Relationship between circulating FGF23 and total body atherosclerosis in the community. Nephrol Dial Transpl. 2009;24:3125–31. doi:10.1093/ndt/gfp205.CrossRef Mirza MA, Hansen T, Johansson L, Ahlstro¨m H, Larsson A, Lind L, et al. Relationship between circulating FGF23 and total body atherosclerosis in the community. Nephrol Dial Transpl. 2009;24:3125–31. doi:10.​1093/​ndt/​gfp205.CrossRef
10.
go back to reference Hu X, Ma X, Pan X, Hao Y, Luo Y, Lu Z, et al. Fibroblast growth factor 23 is associated with the presence of coronary artery disease and the number of stenotic vessels. Clin Exp Pharmacol Physiol. 2015;. doi:10.1111/1440-1681.12467. Hu X, Ma X, Pan X, Hao Y, Luo Y, Lu Z, et al. Fibroblast growth factor 23 is associated with the presence of coronary artery disease and the number of stenotic vessels. Clin Exp Pharmacol Physiol. 2015;. doi:10.​1111/​1440-1681.​12467.
11.
go back to reference Roos M, Lutz J, Salmhofer H, Luppa P, Knauss A, Braun S, et al. Relation between plasma fibroblast growth factor-23, serum fetuin-A levels and coronary artery calcification evaluated by multislice computed tomography in patients with normal kidney function. Clin Endocrinol. 2008;68:660–5.CrossRef Roos M, Lutz J, Salmhofer H, Luppa P, Knauss A, Braun S, et al. Relation between plasma fibroblast growth factor-23, serum fetuin-A levels and coronary artery calcification evaluated by multislice computed tomography in patients with normal kidney function. Clin Endocrinol. 2008;68:660–5.CrossRef
13.
go back to reference Canziani ME, Tomiyama C, Higa A, Draibe SA, Carvalho AB. Fibroblast growth factor 23 in chronic kidney disease: bridging the gap between bone mineral metabolism and left ventricular hypertrophy. Blood Purif. 2011;31:26–32. doi:10.1159/000321368.CrossRefPubMed Canziani ME, Tomiyama C, Higa A, Draibe SA, Carvalho AB. Fibroblast growth factor 23 in chronic kidney disease: bridging the gap between bone mineral metabolism and left ventricular hypertrophy. Blood Purif. 2011;31:26–32. doi:10.​1159/​000321368.CrossRefPubMed
16.
go back to reference North American Symptomatic Carotid Endarterectomy Trial Collaborators. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N Engl J Med. 2011;325:445–53. doi:10.1056/NEJM199108153250701. North American Symptomatic Carotid Endarterectomy Trial Collaborators. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N Engl J Med. 2011;325:445–53. doi:10.​1056/​NEJM199108153250​701.
17.
go back to reference Moore WS, Barnett HJ, Beebe HG, Bernstein EF, Brener BJ, Brott T, et al. Guidelines for carotid endarterectomy: a multidisciplinary consensus statement from the ad hoc committee, American heart association. Stroke. 1995;26:188–201. doi:10.1161/01.STR.26.1.188.CrossRefPubMed Moore WS, Barnett HJ, Beebe HG, Bernstein EF, Brener BJ, Brott T, et al. Guidelines for carotid endarterectomy: a multidisciplinary consensus statement from the ad hoc committee, American heart association. Stroke. 1995;26:188–201. doi:10.​1161/​01.​STR.​26.​1.​188.CrossRefPubMed
19.
go back to reference Stary HC, Chandler AB, Dinsmore RE, Fuster V, Glagov S, Insull W Jr, et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerotic. A report from the committee on vascular lesions of council on atherosclerosis, american heart association. Circulation. 1995;92:1355–74. doi:10.1161/01.CIR.92.5.1355.CrossRefPubMed Stary HC, Chandler AB, Dinsmore RE, Fuster V, Glagov S, Insull W Jr, et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerotic. A report from the committee on vascular lesions of council on atherosclerosis, american heart association. Circulation. 1995;92:1355–74. doi:10.​1161/​01.​CIR.​92.​5.​1355.CrossRefPubMed
20.
21.
go back to reference Straface G, Biscetti F, Pitocco D, Bertoletti G, Misuraca M, Vincenzoni C, et al. Assessment of the genetic effects of polymorphisms in the osteoprotegerin gene, TNFRSF11B, on serum osteoprotegerin levels and carotid plaque vulnerability. Stroke. 2011;42:3022–8. doi:10.1161/STROKEAHA.111.619288.CrossRefPubMed Straface G, Biscetti F, Pitocco D, Bertoletti G, Misuraca M, Vincenzoni C, et al. Assessment of the genetic effects of polymorphisms in the osteoprotegerin gene, TNFRSF11B, on serum osteoprotegerin levels and carotid plaque vulnerability. Stroke. 2011;42:3022–8. doi:10.​1161/​STROKEAHA.​111.​619288.CrossRefPubMed
28.
go back to reference Kataoka Y, Wolski K, Uno K, Puri R, Tuzcu EM, Nissen SE, et al. Spotty calcification as a marker of accelerated progression of coronary atherosclerosis: insights from serial intravascular ultrasound. J Am Coll Cardiol. 2012;59:1592–7. doi:10.1016/j.jacc.2012.03.012.CrossRefPubMed Kataoka Y, Wolski K, Uno K, Puri R, Tuzcu EM, Nissen SE, et al. Spotty calcification as a marker of accelerated progression of coronary atherosclerosis: insights from serial intravascular ultrasound. J Am Coll Cardiol. 2012;59:1592–7. doi:10.​1016/​j.​jacc.​2012.​03.​012.CrossRefPubMed
30.
go back to reference Arnlov J, Carlsson AC, Sundstrom J, Ingelsson E, Larsson A, Lind L, et al. Higher fibroblast growth factor-23 increases the risk of all-cause and cardiovascular mortality in the community. Kidney Int. 2013;83:160–6. doi:10.1038/ki.2012.327.CrossRefPubMed Arnlov J, Carlsson AC, Sundstrom J, Ingelsson E, Larsson A, Lind L, et al. Higher fibroblast growth factor-23 increases the risk of all-cause and cardiovascular mortality in the community. Kidney Int. 2013;83:160–6. doi:10.​1038/​ki.​2012.​327.CrossRefPubMed
32.
go back to reference van Ark J, Hammes HP, Van Dijk MC, Lexis CP, van der Horst IC, Zeebregts CJ, et al. Circulating alpha-klotho levels are not disturbed in patients with type 2 diabetes with and without macrovascular disease in the absence of nephropathy. Cardiovasc Diabetol. 2013;12:116. doi:10.1186/1475-2840-12-116.PubMedCentralCrossRefPubMed van Ark J, Hammes HP, Van Dijk MC, Lexis CP, van der Horst IC, Zeebregts CJ, et al. Circulating alpha-klotho levels are not disturbed in patients with type 2 diabetes with and without macrovascular disease in the absence of nephropathy. Cardiovasc Diabetol. 2013;12:116. doi:10.​1186/​1475-2840-12-116.PubMedCentralCrossRefPubMed
37.
39.
go back to reference Fliser D, Kollerits B, Neyer U, Ankerst DP, Lhotta K, Lingenhel A, et al. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the mild to moderate kidney disease (MMKD) study. J Am Soc Nephrol. 2007;18:2600–8. doi:10.1681/ASN.2006080936.CrossRefPubMed Fliser D, Kollerits B, Neyer U, Ankerst DP, Lhotta K, Lingenhel A, et al. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the mild to moderate kidney disease (MMKD) study. J Am Soc Nephrol. 2007;18:2600–8. doi:10.​1681/​ASN.​2006080936.CrossRefPubMed
Metadata
Title
Increased FGF23 serum level is associated with unstable carotid plaque in type 2 diabetic subjects with internal carotid stenosis
Authors
Federico Biscetti
Giuseppe Straface
Carlo Filippo Porreca
Giovanni Bertoletti
Claudio Vincenzoni
Francesco Snider
Egidio Stigliano
Vincenzo Arena
Flavia Angelini
Giovanni Pecorini
Antonio Bianchi
Raffaele Landolfi
Andrea Flex
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2015
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/s12933-015-0301-5

Other articles of this Issue 1/2015

Cardiovascular Diabetology 1/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.